CG ONCOLOGY INC. - COMMON STOCK

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

CG Oncology Announces Pricing of Public Offering

12 Dec 2024 19:19:18 By Nasdaq GlobeNewswire

CG Oncology Announces Proposed Public Offering

11 Dec 2024 05:17:23 By Nasdaq GlobeNewswire

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

06 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

05 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

20 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

30 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 Aug 2024 07:23:15 By Nasdaq GlobeNewswire

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

06 Jun 2024 11:14:19 By Nasdaq GlobeNewswire

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

24 May 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

03 May 2024 10:23:00 By Nasdaq GlobeNewswire

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

26 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

24 Apr 2024 09:00:00 By Nasdaq GlobeNewswire